All AbMole products are for research use only, cannot be used for human consumption.
Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor. Palmatine chloride can ameliorate DSS-induced colitis by mitigating colonic injury, preventing gut microbiota dysbiosis, and regulating tryptophan catabolism. In vivo, Palmatine (50 or 100 mg/kg, oral; 7 days) has less distortion of epithelium, and fewer infiltrations of inflammatory cells, resulting in significantly lower histopathological scores, it also significantly suppresses the colonic MPO activity.
| Molecular Weight | 387.86 |
| Formula | C21H22ClNO4 |
| CAS Number | 10605-02-4 |
| Solubility (25°C) | Soluble in warm water |
| Storage | 4°C, dry, protect from light, sealed |
| Related IDO Products |
|---|
| (S)-LY-3381916
(S)-LY-3381916 is an active S-isomer of LY-3381916. (S)-LY-3381916 binds to IDOL with an IC50 value less than 1.5 µΜ. LY-3381916 is a potent, selective and brain penetrated inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1. |
| IDO2-IN-1
IDO2-IN-1 is an orally active and potent Indoleamine 2,3-dioxygenase 2 (IDO2) inhibitor with an IC50 value of 112 nM. IDO2-IN-1 can be used for the research of inflammatory autoimmunity. |
| IDO1/2-IN-1
IDO1/2-IN-1 is the first potent IDO1/IDO2 dual inhibitor with IC50s of 28 nM and 144 nM for IDO1 and IDO2, respectively. |
| IDO1/2-IN-1 hydrochloride
IDO1/2-IN-1 hydrochloride is the first potent IDO1/IDO2 dual inhibitor with IC50s of 28 nM and 144 nM for IDO1 and IDO2, respectively. |
| IDO-IN-18
IDO-IN-18 is an IDO inhibitor. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
